TapewireFind a company

person · Reporting owner

Posner Christopher

Disclosed activity across 2 companies

Tapewire entity
82427
SEC CIK
0001748265

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Tvardi Therapeutics, Inc.CARA · Entity 7579Director · PRESIDENT AND CEOFebruary 28, 2025March 04, 2025
ZEVRA THERAPEUTICS, INC.KMPH · Entity 5212DirectorNovember 28, 2022November 30, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Tvardi Therapeutics, Inc.

Report date February 28, 2025 · Filed March 04, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect13,109 Reported balance After 2025-02-28 transaction · row 1
1 source row

Row 1 · 2025-02-28 · Sale · Disposed 583 · Balance 13,109

F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

ZEVRA THERAPEUTICS, INC.

Report date November 28, 2022 · Filed November 30, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.67 · Expires 2032-11-27DirectNot disclosed Reported balance Holding disclosure · report date 2022-11-28 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 33.33% of the total shares subject to the option vest in equal annual installments beginning on November 28, 2023 through November 28, 2025, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer. The option expires ten years after the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 33.33% of the total shares subject to the option vest in equal annual installments beginning on November 28, 2023 through November 28, 2025, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer. The option expires ten years after the date of grant.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 28, 2025 Filed Mar 4, 2025 21:59 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 583 $4.75 $2,769.25
Disclosure

SEC source: 0001415889-25-006576 · form4-03042025_090317.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,109

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 04, 2025 Filed Feb 7, 2025 00:15 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 372 $4.72 $1,755.84
Disclosure

SEC source: 0001415889-25-003295 · form4-02072025_120231.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,692

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.74 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The total number of securities reported as beneficially owned following the reported transaction reflects the 1-for-12 reverse stock split that was effected by the Issuer on December 30, 2024.

Read SEC document
November 04, 2024 Filed Nov 6, 2024 21:51 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 3,668 $0.29 $1,063.72
Disclosure

SEC source: 0001415889-24-026248 · form4-11062024_091118.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,768

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

Read SEC document
August 01, 2024 Filed Aug 2, 2024 20:05 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 4,149 $0.35 $1,452.15
Disclosure

SEC source: 0001415889-24-020605 · form4-08022024_040806.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,436

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

Read SEC document
May 02, 2024 Filed May 6, 2024 20:15 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 3,936 $0.75 $2,952.00
Disclosure

SEC source: 0001415889-24-012322 · form4-05062024_040544.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,585

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.75 to $0.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 29, 2024 Filed Mar 4, 2024 21:19 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 5,834 $0.89 $5,192.26
Disclosure

SEC source: 0001415889-24-006273 · form4-03042024_090323.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,521

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

Read SEC document
February 08, 2024 Filed Feb 12, 2024 22:10 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 35,575 $0.53 $18,854.75
Disclosure

SEC source: 0001415889-24-003395 · form4-02122024_100215.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,355

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

Read SEC document
February 01, 2024 Filed Feb 5, 2024 21:26 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 4,981 $0.55 $2,739.55
Disclosure

SEC source: 0001415889-24-002513 · form4-02052024_090257.xml · nonDerivative · entry 2

Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,930

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 01, 2024 Filed Feb 5, 2024 21:26 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 GrantCommon Stock 62,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-002513 · form4-02052024_090257.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 226,911

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals.

Read SEC document
November 02, 2023 Filed Nov 3, 2023 20:37 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 3,796 $1.22 $4,631.12
Disclosure

SEC source: 0001209191-23-054332 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,411

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

Read SEC document
August 03, 2023 Filed Aug 4, 2023 21:21 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 4,307 $3.07 $13,222.49
Disclosure

SEC source: 0001209191-23-044636 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,207

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.07 to $3.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
May 05, 2023 Filed May 9, 2023 20:22 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 3,869 $4.40 $17,023.60
Disclosure

SEC source: 0001209191-23-028247 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,514

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

Read SEC document
March 03, 2023 Filed Mar 7, 2023 21:47 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 5,987 $9.71 $58,133.77
Disclosure

SEC source: 0001209191-23-016796 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 176,383

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.60 to $9.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:35 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 GrantStock Option (Right to Buy) · Derivative 250,000 $0.00 Strike: $10.06 $0.00
Disclosure

SEC source: 0001209191-23-015553 · doc4.xml · derivative · entry 1

Posner Christopher · CIK 0001748265 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 1, 2023, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 02, 2023 Filed Feb 3, 2023 23:38 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 4,191 $11.80 $49,453.80
Disclosure

SEC source: 0001209191-23-007170 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,370

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on November 3, 2021 and does not represent a discretionary trade by the Reporting Person.

Read SEC document
November 16, 2022 Filed Nov 18, 2022 22:23 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 14,470 $11.13 $161,051.10
Disclosure

SEC source: 0001209191-22-057948 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,561

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on November 3, 2021, and does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.13 to $11.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 04, 2022 Filed Apr 5, 2022 21:48 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 2,006 $12.67 $25,416.02
Disclosure

SEC source: 0001209191-22-023237 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 201,031

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on May 28, 2021 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on November 3, 2021, and does not represent a discretionary trade by the Reporting Person.

Read SEC document
February 25, 2022 Filed Mar 1, 2022 21:17 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 GrantStock Option (Right to Buy) · Derivative 121,000 $0.00 Strike: $10.46 $0.00
Disclosure

SEC source: 0001209191-22-013988 · doc4.xml · derivative · entry 2

Posner Christopher · CIK 0001748265 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,000

Underlying: Common Stock · 121,000 shares

Expires 2032-02-25

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 25, 2022, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 25, 2022 Filed Mar 1, 2022 21:17 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 GrantCommon Stock 39,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-013988 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 203,037

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 25, 2023, February 25, 2024 and February 25, 2025, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

Read SEC document
October 29, 2021 Filed Nov 3, 2021 12:15 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 GrantStock Option (Right to Buy) · Derivative 566,000 $0.00 Strike: $16.83 $0.00
Disclosure

SEC source: 0001209191-21-062593 · doc4.xml · derivative · entry 3

Posner Christopher · CIK 0001748265 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 566,000

Underlying: Common Stock · 566,000 shares

Expires 2031-10-29

F3 · derivative.exercise_date: 25% of the shares will vest and become exercisable on October 29, 2022 and the remainder will vest over the following 12 equal quarterly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date. These options were granted to the Reporting Person pursuant to the Employment Agreement.

Read SEC document
October 29, 2021 Filed Nov 3, 2021 12:15 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 GrantCommon Stock 142,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-062593 · doc4.xml · nonDerivative · entry 2

Posner Christopher · CIK 0001748265 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,037

F2 · shares: Represents the number of shares underlying RSUs granted to the Reporting Person pursuant to the Employment Agreement. Each RSU represents the contingent right to receive one share of common stock of the Issuer. 25% of the RSUs will vest on October 29, 2022 and the remainder will vest over the following 12 equal quarterly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date.

Read SEC document
October 29, 2021 Filed Nov 3, 2021 12:15 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 GrantCommon Stock 5,941 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-062593 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,037

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to an Employment Agreement, dated October 29, 2021, between the Reporting Person and the Issuer, whereby the Reporting Person is employed as a Senior Advisor to the Issuer effective October 29, 2021 and as President and Chief Executive Officer of the Issuer effective November 9, 2021 (the "Employment Agreement"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs will vest in full on March 31, 2022, subject to the Reporting Person's continued service to the Issuer on such date.

Read SEC document
June 07, 2021 Filed Jun 7, 2021 23:33 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 2,304 $13.04 $30,044.16
Disclosure

SEC source: 0001209191-21-038764 · doc4.xml · nonDerivative · entry 2

Posner Christopher · CIK 0001748265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,096

F2 · shares: Represents the number of shares sold by the Reporting Person to satisfy the Reporting Person's tax obligations resulting from the settlement of vested RSUs on June 3, 2021. The sales were effected pursuant to a "sell-to-cover" arrangement adopted in accordance with Rule 10b5-1 on May 28, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
June 03, 2021 Filed Jun 7, 2021 23:33 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 GrantStock Option (Right to Buy) · Derivative 10,800 $0.00 Strike: $13.06 $0.00
Disclosure

SEC source: 0001209191-21-038764 · doc4.xml · derivative · entry 3

Posner Christopher · CIK 0001748265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,800

Underlying: Common Stock · 10,800 shares

Expires 2031-06-03

F4 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

Read SEC document
June 03, 2021 Filed Jun 7, 2021 23:33 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 GrantCommon Stock 7,200 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-038764 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,400

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

Read SEC document
November 19, 2020 Filed Nov 24, 2020 01:28 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 SaleCommon Stock 2,000 $15.82 $31,638.00
Disclosure

SEC source: 0001209191-20-060097 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,200

Read SEC document
June 04, 2020 Filed Jun 8, 2020 21:46 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 GrantStock Option (Right to Buy) · Derivative 10,800 $0.00 Strike: $15.62 $0.00
Disclosure

SEC source: 0001209191-20-035060 · doc4.xml · derivative · entry 2

Posner Christopher · CIK 0001748265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,800

Underlying: Common Stock · 10,800 shares

Expires 2030-06-04

F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

Read SEC document
June 04, 2020 Filed Jun 8, 2020 21:46 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 GrantCommon Stock 7,200 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-035060 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,200

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

Read SEC document
June 04, 2019 Filed Jun 6, 2019 22:03 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 GrantStock Option (Right to Buy) · Derivative 9,000 $0.00 Strike: $20.44 $0.00
Disclosure

SEC source: 0001209191-19-035225 · doc4.xml · derivative · entry 2

Posner Christopher · CIK 0001748265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2029-06-04

F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2020 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

Read SEC document
June 04, 2019 Filed Jun 6, 2019 22:03 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 GrantCommon Stock 6,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-035225 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2020 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

Read SEC document
August 02, 2018 Filed Aug 6, 2018 21:54 UTC Tvardi Therapeutics, Inc. CARA · Entity 7579 GrantStock Option (Right to Buy) · Derivative 35,000 $0.00 Strike: $17.94 $0.00
Disclosure

SEC source: 0001209191-18-045588 · doc4.xml · derivative · entry 1

Posner Christopher · CIK 0001748265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2028-08-02

F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable in three equal annual installments beginning on August 2, 2019, subject to the reporting person's continued service as a director through each such vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.